INTRODUCTION
One of the main goals in Biospecimen Science is to identify and control the potential bias due to biospecimen processing/quality on the molecular analyses.
Several studies have recently recognized the influence of pre-analytical variables (e.g. warm/cold ischemia times, or delays in processing 1 ) on the integrity of biomolecules.
For example, gene profiling of peripheral blood cells of the patients has the potential to advance our understanding of a variety of human diseases.
Biomarkers can be identified that will improve diagnosis and clinical management of patients. However, in order to optimize the cell gene expression data for translational studies, it is essential to control the pre-analytical variables that produce changes in gene expression, which are unrelated to the disease condition being studied.
Controlling preanalytical variables is a particularly challenging and complex issue, since the influence of a sample's quality on the molecular data obtained from its analysis depends on both the class of biomolecule analyzed (DNA, RNA, protein, metabolite), and the type of analytical method: multiplex vs singleplex; qualitative vs quantitative; and specificity, sensitivity, and robustness of the method against specific preanalytical variations. Biobanking method validation requires knowledge of the preanalytical variables that need to be controlled, but also identification of those factors that do not impact the quality of the biospecimen for a given type of research.
To address this major goal, two main approaches are used in biospecimen science-driven biobanking. The first is to optimize the quality of biospecimen and thus directly minimize and/or control the preanalytical bias. Unfortunately, in most clinical settings there is only limited ability to control pre-analytical variables influencing biomolecule integrity, such as surgery or warm ischemia time.
Therefore, in a clinical context, a second approach must be to retrospectively apply appropriate tests to accurately assess the global biomolecular integrity status of each biospecimen. This process becomes critical for high-throughput; quantitative downstream assays implemented as clinical molecular diagnostics.
Once the most critical points in a biospecimen processing method have been identified, specific tests or markers to assess the quality of the biospecimen are needed. These may be called "surrogate quality biomarkers" or "quality indicators". Currently, there are few appropriate quality control tools that are predictive either of downstream method feasibility (e.g. DNA methylation analysis on DNA extracted from formalin fixed paraffin embedded (FFPE) tissue), and reliability (e.g. feasibility of methylation analysis does not guarantee its accuracy), or diagnostic of upstream biospecimen processing steps (e.g. tissue fixation time) (Figure 1 ). Quality Control, in the form of diagnostics tests of upstream biospecimen processing steps is called "biospecimen molecular diagnostics" or "preanalytical characterization". Ultimately, preanalytical characterization should allow researchers to assess the reliability of a specific type of downstream analysis.
Various steps are needed to solve these issues: (1) the scientific community must agree upon the elements from the lifecycle of the biospecimen that should be documented in scientific publications as has been proposed in Biospecimen Reporting for Improved Study Quality (BRISQ) recommendations 2 , (2), these elements must be codified so that their recording and communication is standardized (e.g. the ISBER Biospecimen Science Working Group has developed a standard preanalytical code that identifies the main preanalytical variables for both liquid and solid biospecimen and their simple derivatives 3 ); and (3) it is critical to perform biospecimen research to identify the key biomarkers that will predict sample integrity and quality 4 .
The quality control assays used to characterize biospecimen are different between viable and non-viable specimens. In the first case, viability and functionality (e.g. pluripotency, response to antigens, motility) are assessed through microscopy, flow cytometry or immunoenzymatic assays. In the case of non-viable specimens, molecular integrity (e.g. protein phosphorylation status, epitope conformation, rRNA degradation, DNA cross linking degree) is generally assessed through immunoenzymatic, electrophoretic and molecular biology assays 5 .
It is critical to define and standardize the assays used to assess molecular integrity of biospecimen procured in a clinical setting because there is no consensus in the literature on which biospecimen quality markers/tools provide the best biospecimen molecular diagnostic performance and information. For example, standard approaches to assess RNA integrity, such as ribosomal RNA measurements and RNA Integrity Number (RIN) are neither sensitive nor specific enough to assess potential bias in downstream gene expression analysis 6 .
The goal of this literature review is to identify tools (markers, assays), that can be used to assess pre-analytical variations for both fluid and solid tissue-derived samples. It is an open question to define the most appropriate assays used to assess biospecimen quality, and methods for standardization between laboratories through External Quality Assessment. Furthermore, it is imperative to define the analytical data that can be reliably obtained within different sample quality categories, and develop methods to overcome pitfalls linked to sample quality issues. The scope of the present review is limited to upstream quality control of the biospecimen. Downstream quality control of the end use results such as gene expression microarray parameters, is outside of the scope of this review. The scope of the review encompasses both the clinical biology and research laboratory settings: on the one hand, information that has previously been published in a clinical setting can be applied to research and on the other hand, high throughput assays currently performed in research may be later implemented in clinical practice.
EVIDENCE-BASED BIOSPECIMEN QUALITY CONTROL TOOLS

Biospecimen Science specific literature compilation:
Members of the ISBER Biospecimen Science Working Group (BSWG) performed PubMed searches using keywords such as "analyte", "stability", "preanalytical", and "specimen", and then compiled all identified publications that dealt with "biomolecules" and "biospecimen analytical behavior". Relevant literature from other sources on the same subjects, including proceedings from meetings, 
Biospecimen Science specific literature review:
Members of the Biospecimen Science Working Group (BSWG) performed a critical review of these literature sources to find previously published data demonstrating that specific biomarkers are particularly unstable and sensitive to preanalytical variations or to find assays that can be used to assess such variations. Therefore, the the objective of the working group to identify unstable analytes was directly opposite to the focus of other authors that identified the analytical stability of specific analytes or high-throughput signatures.
References were classified and reviewed in the following thematic categories: 1) Single analyte (blood, urine). These publications were expected to contain information on the most immediately useful diagnostic markers.
We attempted to identify markers that had an on/off response to specific preanalytical variations e.g. where enzymatic or immunologic activity was completely lost. This situation makes it clear that the change is significant, and that reference absolute values are not needed. An important degree of degradation (e.g. 60% drop in 30 min at room temperature) was also considered to be very important, since we can assume that the presence of the corresponding marker or activity will completely disappear under more stressful conditions (e.g. 2 hours at room temperature).
2) Hormones, cytokines, nutritional indicators (blood). Reference values were expected to be found, at least for clinically important analytes.
3) High-throughput (-omics): arrays (DNA, RNA), mass spectrometry. No absolute reference values were expected to be found but these were expected to contain information on the most immediately useful predictive markers.
4) Functional assays (blood cells).
No absolute reference values were expected to be found. 
Classification of potential quality control tools
Based on the data from the literature review, we evaluated some marker tools using four criteria as follows:
Type of QC tool:
a) diagnostic tools to assess the processing steps of the biospecimen, such as delay of processing, time/type of fixation, or storage duration.
b) predictive tools to assess the feasibility and/or reliability for the downstream analysis, particularly important for high throughput methods (predictive of successful method performance).
Evidence based:
Quality control tools from recommendations that were not evidence-based, were not retained. 3) Not immediately applicable. More "stressful" conditions would need to be applied to the biospecimen in order to assess a suitable threshold.
QC tools in the first category require further validation studies, whereas QC tools in the second and third categories require feasibility or proof-of-principle studies.
Accessibility grade
Another key element for assessing the usefulness of a QC tool is to determine how user-friendly and accessible the corresponding method may be.
1) Readily accessible. Classical laboratory methods (e.g. ELISA, PCR, flow cytometry).
2) Potentially accessible. Methods requiring high throughput platforms (e.g. microarray platform, mass spectrometry platform) that are typically available as a centralized service.
3) Not immediately accessible. "Laboratory-developed" methods.
Identification of potential quality control tools
The "single analyte" group of publications mostly contained targeted stability studies. The specific analytes were measured by methods usually applied in clinical biology.
The "high-throughput" group of publications contained comparisons of gene expression microarray or mass spectrometry data between samples having undergone stressful conditions versus their baseline conditions.
In the "functional assays" group, a variety of cytology specimen types were studied [FFPE, cervical cytology, bone marrow, saliva, buccal specimens, blood, Mass spectrometry studies were carried out on semen and urine and QC was determined by the number of chromatographic peaks generated.
The "pathogens" group mostly contained stability studies of viral pathogen nucleic acids in serum or plasma.
The "hormones and nutritional indicators" group also contained stability studies of those specific molecules.
Diagnostic quality control tools:
The most readily applicable and accessible evidence-based quality control tools are summarized in Table 1 .
For serum and plasma specimens: protease inhibitors, and showed that a 2-hour precentrifugation delay at room temperature induced an 11-to 20-fold increase of GM-CSF, IL1  and G-CSF in blood collected without protease inhibitors and a 7-to 10-fold increase of the same proteins in blood collected with protease inhibitors. Baseline reference levels reported were 214±163 pg/mL for GM-CSF, 9.4±7.7 pg/mL for IL1 and 119±60 pg/mL for G-CSF.
C3 chain and fibrinogen peptides: Marshall et al 13 for the first time used MALDI-TOF and showed a characteristic family of complement C3 chain and fibrinogen peptides generated in citrated plasma, exposed to room temperature for 4 hours. respectively. However, BNP levels in healthy donors are at or near the detection limit of the assay; therefore this quality marker can only be useful in heart failure subjects and is thus not of general use. Clinically significant decrease in ACTH levels was observed after storage at room temperature for 8 hours in EDTA plasma and after only 1 hour in serum.
CD40L: Lengelle et al 17 reported soluble CD40L as a quality control marker allowing the assessment of serum exposure to elevated temperatures. They reported that sCD40L, measured by ELISA, undergoes complete degradation upon 12 hours at 37°C or 48 hours at room temperature. Also, freeze-thaw cycles had no effect on sCD40L levels in serum, the reference intervals were 7-17 ng/mL and the precise threshold below which significant exposure to elevated temperatures can be ascertained is 4.3 ng/mL. Implementation of such a quality control assay would necessitate development of monoclonal antibodies specific to the truncated N-terminal end and intact epitopes, thus allowing the performance of ELISA and calculation of a ratio.
For viable blood cell specimens:
IFN production: Owen et al 31 studied the effect of cryopreservation on apoptosis and T cell responses to different protein and peptide antigens. They showed that long term (1 year) cryopreservation increased apoptosis, as measured by activated caspase 3 antibody staining, and diminished CD4+ and CD8+ T cell responses to both CMV lysate and to staphylococcal enterotoxin B (SEB) in HIV patients, with acute and chronic infection, respectively, measured by IFN production. The mean absolute decrease in the percentage of responding T cells was only about 1% so further research must be done to know if more prolonged cryopreservation has a more dramatic effect on these functional assays.
For tissue specimens:
HPRT gene: Foss et al 32 proposed reverse transcriptase PCR (RT PCR) of the hypoxanthine phosphoribosyltransferase (HPRT) mRNA (168-bp) to assess the quality of paraffin embedded tissue. Two technical advantages of this method are that the primers function with both human and mouse RNA (such a QC tool can be applied to both types of specimens) and that they preclude amplification of genomic DNA. However, though amplification was effective on mouse spleen tissues fixed with Omnifix and Carnoy, it was not effective on FFPE tissues. There is still a lack of consensus regarding which markers/tools are the most useful to assess sample quality. As the impact of biospecimen processing on the quality of the research data is better recognized and understood, it is hoped that a more general effort on identifying useful QA/QC markers/tools will be appreciated in the biospecimen science community.
This review does not present current widely-used quality control assays such as nucleic acid spectrophotometry, RIN, or PCR nor historical QC tools such as the brain tissue pH, (assumed to result from hypoxia 48 ), which has been recently reviewed in the ISBER Best Practices 3 rd edition 5 or suggested in the literature as a form of recommendations 49 . Instead, we review indices for novel and evidence based quality control assays, with reasonable biospecimen molecular diagnostic potential.
Most of the publications reviewed were observational studies in that they observed biospecimen behavior relative to differences in processing or characterization methods. We believe that fundamental biospecimen research is also needed to explain the underlying mechanisms (e.g. protease enzymatic activities underlying protein concentration changes, activation of cellular pathways underlying gene expression changes, oxidation and single strand breaks underlying DNA degradation, methylation-chromatin conformation underlying stem cell pluripotency status). This kind of research could lead to better solutions for stabilizing biospecimen for future research studies.
The main goal of the present literature review is to identify markers or assays for the evaluation of quality of specimens. However, another approach in biospecimen science is to increase the range of molecular techniques that can be applied to specimens, circumventing their inherent challenges, particularly those present in archival FFPE tissues. For example, antigen retrieval (AR) for FFPE material has not only improved IHC and proteomics analysis of . Furthermore, a single universal QC assay cannot cover all aspects of biospecimen characterization. The use of the suggested QC tools is not to certify a biospecimen as being of "high" or "low quality" but to "diagnose" specific preanalytical conditions e.g. a serum sample having undergone more than 24 hours at room temperature conditions. Obviously, the significance of such conditions is different depending on the specific downstream analyte, different analytes having different robustness to the same conditions. Therefore, a panel of carefully selected QC markers will be needed to comprehensively assess biospecimen quality and specific knowledge on the impact of specific collection / processing conditions on each downstream assay will be required.
Another challenge is the lack of population reference ranges for the majority of research biomarkers. As can be seen in Figure 3 , the usefulness of a surrogate quality biomarker can only be assessed if we know the corresponding population reference ranges. Figure 3 shows a model of surrogate quality control markers with either linear or exponential degradation rate upon specific preanalytical conditions. Knowledge of the baseline reference intervals in the population of interest is necessary in order to be able to define the lower threshold value of the analyte below which we can be certain that the biospecimen underwent conditions more stressful than the ones of the corresponding intercept. In the have undergone more than 2 preanalytical factor stress units. Diagnostic performance depends on the degradation kinetics. It is obvious, with the degradation kinetics shown in Figure 3 , that a biospecimen molecular diagnostic tool with linear degradation will be more specific, whereas one with exponential degradation will be more sensitive. When defining quality control thresholds, one must know the reference ranges in both healthy and diseased subjects 4 and also take into account the analytical imprecision. Only then can we define a marker cut-off beyond which we can be certain that a biospecimen has undergone a minimum amount of a specific "preanalytical stress" independently of the initial level of the marker used. For high-throughput studies in which thousands of data points are generated on a single sample, a traditional "absolute value" for the reference is not available. only because high-throughput approaches are usually expensive, but also clinical specimens are precious and might be the limiting factor, especially for research.
For "predictive markers", authors of many papers "recommend" some number/threshold, such as using RNA with certain parameters, etc., but this recommendation is usually not based on proven evidence.
In some cases, animal models can allow us to identify QC tools applicable to human biospecimen. For example, post mortem salmon RNA stability has been shown to be tissue-type dependent 60 
